WWP1 inhibition increases SHP2 inhibitor efficacy in colorectal cancer
The protein tyrosine phosphatase SHP2 plays a key role in activating RAS signaling, but its inhibitors are widely resistant in colorectal cancer (CRC). We reveal WWP1-PTEN-AKT signaling pathway is involved in the resistance of SHP2 inhibition. Combined inhibition of WWP1 and SHP2 exerts a synergistic lethal effect in CRC cells. Expression levels of WWP1 and SHP2 contribute to prognostic modeling in CRC patients. These findings may assist in individual clinical decision-making and clinical trial design, especially for patients with KRAS-mutant CRC.
Follow the Topic
-
npj Precision Oncology
An international, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications to clinical medicine.
Related Collections
With collections, you can get published faster and increase your visibility.
Noninvasive biomarkers: bridging real-world evidence and clinical trial data
Publishing Model: Open Access
Deadline: Sep 13, 2025
Tumor-type-agnostic biomarkers and treatments in oncology
Publishing Model: Open Access
Deadline: Sep 05, 2025
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in